DMTX Dimension Therapeutics, Inc.

1.50
+0  (3%)
Previous Close 1.45
Open 1.45
Price To book 0.61
Market Cap 37.56M
Shares 25,043,000
Volume 37,731
Short Ratio 1.89
Av. Daily Volume 175,956

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial initiated December 2016. Initial data due 2H 2017.
DTX101
Ornithine Transcarbamylase (OTC) Deficiency
Phase 1/2 initial data released January 31, 2017.
DTX101
hemophilia B

Latest News

  1. ETFs with exposure to Dimension Therapeutics, Inc. : April 7, 2017
  2. Edited Transcript of DMTX earnings conference call or presentation 9-Mar-17 1:30pm GMT
  3. Dimension Therapeutics, Inc. :DMTX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
  4. Dimension Therapeutics, Inc. :DMTX-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
  5. Can The Uptrend Continue for Dimension Therapeutics (DMTX)?
  6. Dimension Therapeutics Announces Full Year 2016 Financial Results and Recent Updates Across Rare and Metabolic Disease Portfolio and in HeLa Manufacturing
  7. Dimension Therapeutics to Hold Full Year 2016 Financial Results and Recent Program Updates Conference Call
  8. Lifshitz & Miller LLP Announces Investigation of BT Group plc, Celadon Group, Inc., Community Health Systems, Inc., Dimension Therapeutics, Inc., Home Capital Group Inc., Lifevantage Corporation, OvaScience, Inc. and Under Armour, Inc.
  9. Newman Ferrara LLP Announces Corporate Governance Investigation of Dimension Therapeutics Inc.
  10. Cerner's EHR Platform to Enhance Health Care at San Juan NGO
  11. Dimension Therapeutics Elects Dr. John A. Hohneker to Its Board of Directors
  12. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Dimension Therapeutics, Inc.
  13. Dimension Announces Interim Topline Results from Ongoing Phase 1/2 Clinical Program for DTX101, Dimension’s Lead AAV Product Candidate in Development for Adult Patients with Moderate/Severe to Severe Hemophilia B
  14. vTv Therapeutics (VTVT) in Focus: Stock Moves 6.7% Higher
  15. Is Dimension Therapeutics Inc (DMTX) Going to Burn These Hedge Funds?
  16. Here’s What We Are Looking For From The Upcoming Dimension Therapeutics Inc (DMTX) Data
  17. ETFs with exposure to Dimension Therapeutics, Inc. : November 14, 2016